Syntis Bio Taps IPO Veteran as CFO, Signaling Major Push in Obesity Market

BOSTON, MA – June 09, 2026 – Clinical-stage biopharmaceutical company Syntis Bio has appointed Matthew Dallas as its Chief Financial Officer, a move that signals a significant escalation in its strategic ambitions. While a new CFO hire is standard corporate procedure, bringing on a figure known for navigating a biotech from its initial public offering to a nearly billion-dollar acquisition sends a clear message to investors and competitors alike: Syntis Bio is preparing for its next major financial act.

Dallas joins a company aiming to carve out a niche in the fiercely competitive, $100 billion-plus obesity market, a field currently dominated by giants like Novo Nordisk and Eli Lilly. Syntis Bio’s strategy, however, hinges not on competing directly with the prevailing GLP-1 agonists, but on pioneering a fundamentally different approach. The hiring of a seasoned financial architect like Dallas suggests the company believes its unique science is ready for the financial primetime.

“With Matt’s appointment, we continue to assemble a leadership team with the expertise and experience needed to scale Syntis Bio’s financial and business infrastructure,” said Rahul Dhanda, Chief Executive Officer of Syntis Bio, in a statement. Dhanda highlighted Dallas’s experience in navigating “the full arc of building a biopharmaceutical company,” a nod to a career defined by high-stakes financial maneuvers.

The Architect of Exits

Matthew Dallas is not just any biotech CFO. His resume is a testament to his ability to guide companies through critical financial inflection points. His most notable tenure was at CoLucid Pharmaceuticals, where he was instrumental in leading the company through a $55 million IPO in 2015. Just two years later, he helped orchestrate its acquisition by Eli Lilly for an impressive $960 million in cash, a deal driven by CoLucid’s promising migraine treatment. This track record of creating significant shareholder value is precisely what a company like Syntis Bio, with a disruptive technology platform, looks for in a financial leader.

His experience is deeply rooted in the metabolic disease space as well. Prior to his most recent role at Pulmocide, Dallas served as CFO of Zealand Pharma, a Danish firm specializing in peptide-based medicines for diabetes and obesity. This direct experience with the commercial and financial challenges of the metabolic therapeutic market provides him with a unique perspective on the landscape Syntis Bio is entering. He understands the science, the competition, and, most importantly, the financial pathways to success.

“I’m excited to join Syntis and for the opportunity to be part of a company developing the next generation of solutions for metabolic health,” Dallas stated. His focus, he noted, will be on scaling the business through “financial strategies that translate into significant value creation.” For a company at Syntis Bio’s stage, this translates to securing the substantial capital required for late-stage clinical trials and building an operational framework capable of supporting a potential blockbuster drug.

A New Weapon in the Obesity Wars

Syntis Bio’s confidence stems from its novel technology, which stands apart from the current wave of GLP-1 therapies like Wegovy and Zepbound. The company’s lead candidate, SYNT-101, is a once-daily oral pill that embodies a “gastric bypass in a pill” concept. Instead of systemically activating hormone receptors throughout the body, SYNT-101 uses a proprietary mussel-inspired polymer to create a temporary, non-absorbable lining in the duodenum, the first part of the small intestine.

This synthetic lining, which lasts for up to 24 hours before being naturally cleared, physically blocks nutrient absorption in the upper gut and redirects food to the lower small intestine. This redirection mimics the anatomical changes of gastric bypass surgery, naturally stimulating the body’s own production of satiety hormones, including GLP-1. The critical difference is that it’s a non-invasive, temporary, and gut-restricted mechanism.

The potential advantages are significant. A key challenge with current GLP-1 drugs is the loss of lean muscle mass alongside fat, as well as prevalent gastrointestinal side effects. Syntis Bio’s preclinical data for SYNT-101 showed a consistent 1% weekly weight loss in rodent models while preserving 100% of lean muscle mass. Furthermore, an early first-in-human pilot study reported no adverse events or GI symptoms, suggesting a potentially more tolerable patient experience. With the first patient now dosed in its Phase 1/1b SYNTIETY-1 clinical trial in Australia, the industry is watching closely to see if these promising early results hold up.

The Financial Blueprint for Growth

The appointment of Dallas arrives as Syntis Bio is well-capitalized but facing the immense future costs of late-stage drug development. The company has successfully raised $65.9 million to date, including an oversubscribed $33 million Series A round in July 2025 led by Cerberus Ventures and supported by a strong syndicate of investors. This funding, augmented by non-dilutive grants from the NIH, has propelled SYNT-101 into the clinic.

However, the journey from Phase 1 to market is a multi-hundred-million-dollar endeavor. Dallas's immediate task will be to fortify the company's financial foundation for this journey. His expertise in both public and private financing strategies will be crucial in planning the next capital raise, which could come in the form of a larger private round, a strategic partnership with a major pharmaceutical player, or an initial public offering.

Bringing on a CFO with a successful IPO and M&A track record this early in the clinical process is a strategic play. It not only prepares the company for a potential public listing but also signals to potential partners and acquirers that Syntis Bio is being managed with an eye toward a major value-creation event. As one industry analyst noted, “You don’t hire a CFO like Matt Dallas unless you’re planning to build something big, take it public, or sell it for a premium. Syntis Bio just put all three of those options squarely on the table.”

Beyond the Blockbuster: A Platform for the Future

While the massive obesity market is the immediate prize, Syntis Bio’s ambitions extend further. The SYNT™ platform is not a one-trick pony. Its core technology—the ability to apply a temporary, functional coating to the small intestine—has broad applications. The company is already leveraging this versatility to develop SYNT-202, an enzyme replacement therapy for the rare pediatric metabolic disorder homocystinuria, which is also slated for Phase 1 studies.

In addition, the platform has demonstrated the potential to dramatically enhance the oral bioavailability of other drugs, potentially transforming injected biologics into oral pills. This positions Syntis Bio not just as a therapeutics company, but as a platform technology company with opportunities for licensing and partnerships across a wide range of diseases.

With Dallas managing the financial strategy, Syntis Bio is now armed with both a disruptive scientific platform and the leadership to finance its path to market. As the company advances its clinical trials, the combination of novel science and shrewd financial stewardship could make it a formidable new force in the evolving landscape of metabolic health.